Showing results (131-140 of 577) with videos related to
Sort By:
Pageof 58
Pancreas|March 7, 2013
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancerRichard A Hubner, Fiona Worsnop, David Cunningham, et al.The Oncologist|October 23, 2012
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Sarah Barton, Eliza A Hawkes, Andrew Wotherspoon, et al.The Oncologist|June 3, 2011
Targeting angiogenesis in esophagogastric adenocarcinomaAlicia F C Okines, Andrew R Reynolds, David CunninghamTherapeutic Advances in Medical Oncology|December 22, 2018
Immunotherapy and pancreatic cancer: unique challenges and potential opportunitiesKate Young, Daniel J Hughes, David Cunningham, et al.Journal of Geriatric Oncology|September 28, 2013
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapyLisa Lowry, Paul Smith, David Cunningham, et al.Clinical Colorectal Cancer|February 19, 2008
Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive markerDiletta Bianchini, Akali Jayanth, Yu Jo Chua, et al.Drugs|November 24, 2007
Pharmacotherapy for oesophagogastric cancerChristopher Jackson, Naureen Starling, Yu Jo Chua, et al.Nature Reviews. Clinical Oncology|May 15, 2026
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizonsHongcheng Zhu, Florian Lordick, Yelena Y Janjigian, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2005
Site of relapse after chemotherapy alone for stage I and II Hodgkin's diseaseMehdi Shahidi, Nahid Kamangari, Sue Ashley, et al.Chinese Journal of Cancer|May 7, 2013
Targeting the PI3K-AKT-mTOR signaling network in cancerKhurum H Khan, Timothy A Yap, Li Yan, et al.Pageof 58